Published in Cancer on March 01, 1981
Rare cancers and specialist centres. Br Med J (Clin Res Ed) (1986) 1.73
Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours. Postgrad Med J (1985) 0.97
Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. Proc Natl Acad Sci U S A (1983) 0.84
Chemotherapy for non-seminomatous germ-cell tumours. J R Soc Med (1985) 0.75
Update in cancer chemotherapy: genitourinary tract cancer, Part 4: Testicular cancer. J Natl Med Assoc (1988) 0.75
Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg (1984) 3.96
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Epidemiology of cancer of the prostate. Cancer (1971) 2.19
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci U S A (1981) 2.09
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Malignant schwannoma--clinical characteristics, survival, and response to therapy. Cancer (1981) 2.04
Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol (1998) 2.03
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med (1981) 1.97
Extraosseous osteogenic sarcoma. A review of 48 patients. Cancer (1983) 1.93
Growth and differentiation of human nasal epithelial cells in culture. Serum-free, hormone-supplemented medium and proteoglycan synthesis. Am Rev Respir Dis (1985) 1.87
Recent results of management of palpable clinically localized prostate cancer. Cancer (1993) 1.78
The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (1994) 1.73
Impact of transurethral resection on the long-term outcome of patients with prostatic carcinoma. J Urol (1993) 1.72
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol (1986) 1.63
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
Intermittent endocrine therapy for advanced prostate cancer. Cancer (1986) 1.60
Sarcomas of the kidney. J Urol (1984) 1.58
Epidemiology of adenocarcinoma of the kidney. J Natl Cancer Inst (1974) 1.58
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Experience with carcinoma of the scrotum. J Urol (1977) 1.57
Malignant mesothelioma of the pleura: review of 123 patients. Cancer (1982) 1.55
The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol (1981) 1.55
Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann Surg (1973) 1.53
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs (1997) 1.53
Cryptorchidism and testicular cancer. J Urol (1980) 1.52
Solitary metastasis from renal cell carcinoma. J Urol (1975) 1.52
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Spermatic cord sarcoma in adults. J Urol (1978) 1.48
125I implantation for carcinoma of prostate. Further follow-up of first 100 cases. Urology (1982) 1.47
Does surface chemistry affect thrombogenicity of surface modified polymers? J Biomed Mater Res (2001) 1.45
Septicemia caused by Capnocytophaga in a granulocytopenic patient with glossitis. Arch Intern Med (1980) 1.44
Review of an 8-year experience with modifications of endoscopic suspension of the bladder neck for female stress urinary incontinence. J Urol (1990) 1.43
Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ (1995) 1.41
Management of clinically localized prostatic cancer. An unresolved problem. JAMA (1993) 1.40
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol (1999) 1.40
Testicular cancer in cryptorchids. Cancer (1982) 1.39
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol (2002) 1.39
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am (2006) 1.38
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res (1983) 1.38
Cystectomy + diversion for carcinoma of the bilharzial bladder. Prog Clin Biol Res (1988) 1.37
Toxicity of E. coli L-asparaginase in man. Cancer (1970) 1.36
Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol (2000) 1.35
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol (2001) 1.33
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. Proc Natl Acad Sci U S A (2000) 1.32
Initiation of multi-leaf collimator conformal radiation therapy. Int J Radiat Oncol Biol Phys (1993) 1.32
Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol (1994) 1.31
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol (2000) 1.29
Effect of catecholamines on ion transport in dog tracheal epithelium. J Appl Physiol Respir Environ Exerc Physiol (1979) 1.28
Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer (1982) 1.27
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Lymphangiosarcoma. Cancer (1981) 1.26
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol (1977) 1.24
The evolution of mature teratoma from malignant testicular tumors. Cancer (1977) 1.24
The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer (1977) 1.24
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer (1987) 1.23
Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg (1984) 1.23
Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer (1974) 1.22
Natural history and staging of prostate cancer. Urol Clin North Am (1984) 1.21
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). J Clin Oncol (1985) 1.19
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol (1997) 1.18
Penile cancer: relation of extent of nodal metastasis to survival. J Urol (1987) 1.16
Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer (1977) 1.16
Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep (1976) 1.15
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. J Histochem Cytochem (1984) 1.15
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci U S A (1985) 1.14
Proceedings: The natural history of prostatic cancer. Cancer (1973) 1.14
Regional lymph node metastasis from bladder cancer. J Urol (1981) 1.14
Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report. Cancer (1985) 1.13
Lymphocyte stimulation: selective destruction of cells during blastogenic response to transplantation antigens. Science (1971) 1.13
Complications of 125iodine implantation and pelvic lymphadenectomy in the treatment of prostatic cancer. J Urol (1979) 1.13
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol (1996) 1.13
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Malignant tumors of the spermatic cord. Cancer (1969) 1.13
Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer (1996) 1.11
Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol (1988) 1.11
cis-Platinum ototoxicity. Clin Toxicol (1978) 1.11
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer (1987) 1.10
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer (1996) 1.10
Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys (1995) 1.10
Selected experience with surgery and combination chemotherapy in the treatment of nonseminomatous testis tumors. J Urol (1983) 1.09
Expectant management of clinically localized prostatic cancer. J Urol (1994) 1.09
Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet (1987) 1.09
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol (1988) 1.08
Primary carcinoma of the ureter: a prognostic study. Cancer (1975) 1.08
Implantation of 125I in prostatic cancer. Surg Clin North Am (1974) 1.08
Small cell carcinoma of the lung: experience with six-drug regimen. Cancer (1980) 1.08